Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Lexaria Bioscience Corp WT
(NQ:
LEXXW
)
0.8000
UNCHANGED
Streaming Delayed Price
Updated: 12:08 PM EST, Dec 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Lexaria Bioscience Corp WT
< Previous
1
2
3
4
5
6
7
Next >
Lexaria’s Human Clinical Nicotine Study Completes Dosing as Planned
May 08, 2023
Via
ACCESSWIRE
Lexaria Awards CRO Contract for Upcoming U.S. Phase 1b Hypertension Study
April 24, 2023
Via
ACCESSWIRE
Lexaria is Receiving Four New Patents
April 20, 2023
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Encouraging Results from DehydraTECH-CBD Diabetes Study
March 02, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria's DehydraTECH-CBD Diabetes Study Demonstrates Weight Loss, Improved Triglyceride and Cholesterol Levels
March 02, 2023
Via
ACCESSWIRE
Lexaria's Human Clinical Hypertension Study a Success
October 27, 2022
Via
ACCESSWIRE
Lexaria Discusses Valuation Metrics for Biotech Industry
August 11, 2022
Via
ACCESSWIRE
Lexaria Discovers Potential Novel Mechanism From Hypertension Study HYPER-H21-4
February 21, 2023
Via
ACCESSWIRE
Former President of GW Pharmaceuticals USA Joins Lexaria Bioscience as Strategic Advisor
January 23, 2023
Via
ACCESSWIRE
Lexaria Releases Annual Letter from the CEO
January 13, 2023
Via
ACCESSWIRE
Lexaria Receives First Granted Patent in Canada
December 29, 2022
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD (TM) Achieves Superior CBD Blood Absorption Levels in Hypertension Study
December 21, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Lexaria's DehydraTECH-CBD Achieves Superior Human Blood Absorption Levels
December 21, 2022
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Dosing in Its Human Oral Nicotine Study
December 20, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria’s Human Oral Nicotine Study Begins Dosing
December 20, 2022
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD(TM) Demonstrates Enhanced Performance Compared to Leading Anti-Seizure Medication
November 29, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria’s DehydraTECH-CBD(TM) Enhances Performance Compared to Epidiolex(R) in Seizure Study Program
November 29, 2022
Via
ACCESSWIRE
Lexaria Examining Potential Therapeutic Use of DehydraTECH-CBD in Dementia
November 10, 2022
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences 1st-Ever Study Evaluating DehydraTECH-CBD’s Effect on Diabetes
November 08, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Starts Study Evaluating the Effect of DehydraTECH-CBD on Diabetes
November 08, 2022
Via
ACCESSWIRE
Lexaria Receives Independent Review Board Approval for its Upcoming Human Oral Nicotine Study
November 01, 2022
Via
ACCESSWIRE
Lexaria Bioscience: Taking Aim at the $28 Billion Hypertension Market; Human Clinical Study Yields Remarkable Results
September 20, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
Product Safety
Lexaria Welcomes Dr. Catherine Turkel to its Board of Directors
September 02, 2022
Via
ACCESSWIRE
Lexaria Receives New Patent in Mexico
August 31, 2022
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Positive FDA Feedback Concerning Opening IND Program
August 10, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Lexaria Announces Positive Feedback from Pre-IND Meeting with FDA on DehydraTECH-CBD for Hypertension
August 10, 2022
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD Hypertension Study Completes Dosing with No Serious Adverse Events
July 27, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria's DehydraTECH-CBD Hypertension Study HYPER-H21-4 Dosing Complete with No Serious Adverse Events
July 27, 2022
KELOWNA, BC / ACCESSWIRE / July 27, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that...
From
Lexaria Bioscience Corp.
Via
AccessWire
Exposures
Product Safety
Lexaria's DehydraTECH-CBD Hypertension Study HYPER-H21-4 Dosing Complete with No Serious Adverse Events
July 27, 2022
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Licensee Launches Ko Brand in Preparation to Deploy DehydraTECH CBD Products in Japan
July 26, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.